Nontuberculous Mycobacteria Infection Pipeline Therapies and Latest Breakthroughs 2020
“Nontuberculous Mycobacterial Infections Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial Infections market.
Nontuberculous Mycobacteria Infection Disease Overview
Nontuberculous Mycobacterial Infection is caused by nontuberculous mycobacteria, which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems.
The severity and signs and symptoms of infections vary with person to person. Sometimes NTM infections causes skin diseases and inflammations. People with underlying disease such COPD, asthma, cystic fibrosis, AAD, and other lung disease are at risk of developing Nontuberculous mycobacterial lung disease, however, in some rare cases, people with no history of lung disease can also get affected.
Know more about report offerings: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight
Key Companies in Nontuberculous Mycobacterial Infection Market
- Insmed Incorporated
- RedHill Biopharma
- Novoteris
- Savara
- Beyond Air
Nontuberculous Mycobacterial Infection Pipeline Therapies
- RHB-204: RedHill Biopharma
- Thiolanox: Novoteris
- Molgradex: Savara
- Arikayce: Insmed Incorporated
- Nitric Oxide: Beyond Air
Read More: https://www.delveinsight.com/blog/nontuberculous-mycobacterial-infection-market-size/
Of the emerging therapies, the most anticipated therapy in the NTM infections market to get launched is, Arikayce, an aminoglycoside antibacterial, of Insmed Incorporated.
A detailed picture of the Nontuberculous Mycobacterial Infections pipeline landscape is provided, which includes the disease overview and Nontuberculous Mycobacterial Infections treatment guidelines. The assessment part of the report embraces in-depth Nontuberculous Mycobacterial Infections commercial assessment and clinical assessment of the Nontuberculous Mycobacterial Infections pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacterial Infections collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Request For Sample Pages: https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight
Scope of the report
- The Nontuberculous Mycobacterial Infections report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Nontuberculous Mycobacterial Infections across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Nontuberculous Mycobacterial Infections therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Nontuberculous Mycobacterial Infections research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Nontuberculous Mycobacterial Infections.
Table of Contents
1. Report Introduction
2. Nontuberculous Mycobacterial Infections
3. Nontuberculous Mycobacterial Infections Current Treatment Patterns
4. Nontuberculous Mycobacterial Infections – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Nontuberculous Mycobacterial Infections Late Stage Products (Phase-III)
7. Nontuberculous Mycobacterial Infections Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Nontuberculous Mycobacterial Infections Discontinued Products
13. Nontuberculous Mycobacterial Infections Product Profiles
14. Nontuberculous Mycobacterial Infections Key Companies
15. Nontuberculous Mycobacterial Infections Key Products
16. Dormant and Discontinued Products
17. Nontuberculous Mycobacterial Infections Unmet Needs
18. Nontuberculous Mycobacterial Infections Future Perspectives
19. Nontuberculous Mycobacterial Infections Analyst Review
20. Appendix
21. Report Methodology
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/
